According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose material adverse facts about the Company’s business operations and prospects. Specifically, defendants:

• inflated the Company’s true ability to successfully file a Biologics License Application (BLA) for Ampion;
• inflated the results of the AP-013 study of Ampion (the Company’s lead product with “unique immunomodulatory action and anti-inflammatory effects” used to treat individuals with inflammatory conditions including, but not limited to, severe osteoarthritis of the knee (OAK)) and the timing of unblinding the data from the AP-013 study; and
• that, as a result, of the foregoing, defendants’ statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Attorney Advertising. Prior results do not guarantee a similar outcome.